BG SALES-TRADING MORNING DU 07/09/2016

LA SEANCE DE LA VEILLE											
INDICES U.S & JAPON					SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS			
Indices	Cloture	Var %	Var 17h3 (en 9		S&P	Var %	YTD	stoxx	Var %	YTD	
DJ	18538,1	0,2%	0,29	%	Oil & Gaz	1,5	15,1	Real Estate	0,3	-0,2	
NASDAQ	5275,9	0,5%	0,2%		Auto	1,2	-4,1	Auto & Part	0,2	-12,8	
S&P 500	2186,5	0,3%	0,2%		Utilities	1,1	15,1	Basic Resources	0,2	28,1	
NIKKEI	17012,3	-0,4%	-		Real Estate	1	9,2	Media	0,2	-6,4	
SECTEURS S&P : WORST PERFS. SECTEURS STOXX : WORST PERF											
					S&P	Var %	YTD	STOXX	Var %	YTD	
					Banks	-0,8	-3,7	Banks	-1,7	-20,5	
					Cap Goods	-0,5	10,1	Oil & Gas	-0,9	9,7	
					Consumer Durables	-0,4	3,9	Technology	-0,7	1,7	
					MEDIAS	-0,4	4,6	Travel & Leisure	-0,4	-12,1	

Valeurs les plus traitées hier vs. Moy. 3M										
CA	AC 40		EURO S	TOXX 50		STOXX 600				
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%		
PUBLICIS GROUPE	68,9	2,1	FRESENIUS SE & CO	70,4	6,4	INGENICO GROUP	79,4	-13,6		
VEOLIA ENV	20,6	0,7	BAYER AG-REG	95,9	1,8	COFINIMMO	114,6	3,3		
AIRBUS GROUP SE	54,4	1	AIRBUS GROUP SE	54,4	1	ARM HOLDINGS PLC	1700	-		
VALEO SA	49,4	1,4	UNICREDIT SPA	2,3	-1,5	SFR GROUP SA	25,3	-0,9		
TECHNIP SA	53	-1	ESSILOR	117	0,3	FRESENIUS SE & CO	70,4	6,4		

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

	DEVISES				MAT. PREMIERES						
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	100	0%	0,7%	€/\$	1,126	0,2%	3,6%	BRENT	46,6	-0,2%	30,4%
U.S 10 ANS	99,7	0%	1,5%	€/¥	114,15	0,6%	14,4%	ONCE OR (\$)	1351	0,3%	27,2%
VIX Index		0,3%			VSTOXX	Index	19,1	3	8,7%		

Economic Calendar

JP - Leading index Jul. (100A 98.6E) DE - Industrial Prod. N.s.A. Jul (0.2% E) UK - Industrial Prod. (1.7%E) US - Beige Book

Dividends Calendar ex-date next day SHIRE 3.51p (0.07%) Ex Div today

Markets Recap (source Street account)

Asian markets are narrowly mixed on Wednesday. Trading activity is again fairly subdued on the major indices. The Nikkei came under some pressure earlier with the dollar-yen nearing its lowest since the Jackson Hole symposium. Amid confusion over how the BoJ will proceed with policy, Japanese press have suggested a split is developing between officials on whether to ease as well as on the appropriate policy mix. Ex- member Momma was the latest former official to advocate leaving policy unchanged in September.

Greater Chinese markets are mixed in quiet trade. Mainland markets are logging modest gains amid limited newsflow while the PBoC fixed the yuan higher following the dollar's latest bout of selling. Elsewhere, an in-line Australian GDP result revealed growth accelerated amid support from household and government spending. The Aussie has largely held its overnight strength as it nears its pre-Jackson Hole highs.

Copper has led gains in the commodities complex with the US dollar continuing to push lower. Market-implied odds of a rate hike in December have fallen below 50% following the soft August ISM non-manufacturing print. However Fed officials continue to maintain a comparatively hawkish stance with San Francisco Fed's Williams repeating his call for a rate hike to occur sooner rather than later **US equities were higher today.** Treasuries were stronger across the curve. The dollar was markedly weaker, particularly on the yen cross. Gold settled up 2.1%. Silver rose 4%, logging its best session since early July. Oil was mixed, following some disappointment about yesterday's Russia/Saudi cooperation agreement. WTI settled up 0.9% and Brent finished down 0.8%.

The August ISM non-manufacturing index disappointed, with the release noting weaker business activity and new orders. The report put strong pressure on the dollar and boosted Treasuries. There were few other drivers today, with the September-or-December interest-rate debate continuing to dominate the discussion.

There were several M&A headlines today, including BAYN.GR increasing its offer for MON and DHR buying CPHD. VOW.GR announced a strategic alliance with NAV and took a 16.6% stake. SSYS and DDD were boosted by GE's purchase of two European 3D printing firms. On the earnings front, MRVL earnings beat but revenue missed and guidance was disappointing.

Multis and machinery stocks were weaker. Banks lagged. Industrial and precious metals rallied, but chemicals weighed on materials. Media and retail names were a drag on consumer discretionary. Pharma and biotech helped healthcare. Internet and social-media names were stronger. Energy led the market.

Stocks Factor to watch today :

FUTURES 08h00 : Es50 +0.4%, DAX +0.3%, CAC +0.3%, FTSE +0.4%

FRESENIUS HELIOS : to acquire 100% stake in IDC SALUD HOLDING

SCOR : Launches its new strategic plan.

U.S. DOLLAR : plunges after weak ISM data

INTERPARFUMS: H1 revenue €162.3m vs. 147.1 year ago.

ALTRAN : has made a minority equity investment in DIVERGENT, they wil jointly go to market in the U.S., in Europe and China to deploy new technologies to improve the car manufacturing industry.

Rating & TP Changes

FRESENIUS : TP raised to ξ 78 vs. 73 *@Bryan Garnier* **CRH** : TP raised to ξ 37 vs. 32 *@Jefferies* **REMY COINTREAU** : TP raised to ξ 88 vs. 80, BUY*@HSBC* **INDITEX** : raised to BUY *@SocGen* **SWORD** : TP raised To ξ 27 vs. 26, BUY *@Bryan Garnier* **SCHNEIDER** : TP raised to ξ 49 vs. 45 *@UBS* **LEGRAND** : TP raised to ξ 59 vs. 53 *@UBS* **ERYTECH** : TP cut to ξ 46 vs. 48, BUY *@Bryan Garnier* **LUXOTTICA** : TP cut to ξ 47 vs. 52 *@UBS* **NESTLE** : MARKET PERFORM vs. OUTPERFORM *@Bernstein* **RECKITT BENCKISER** : NEUTRAL vs. OUTPERFORM *@EXANE*

Technical Analysis

HIGHEST YTD : ARKEMA, FRESENIUS, PUBLICIS, SAFRAN, SOLVAY, TELEPERFORMANCE, VALEO LOWEST YTD : ERICSSON, INGENICO, NOVO NORDISK RSI 14d OVERSOLD : INGENICO

TUpward Signals

C. DIOR : 50D MAV crossing upward 200d MAV

Telecom services

WORLDPAY

With the Q2 earnings season coming to an end, French Telecom market still appears very much under promotional pressure, but the worst case scenario we could fear following the breakdown of consolidation talks did not happen. The market is showing some tiny signs of recovery and H2 might confirm trends globally improving. In this context we continue to favour Iliad, but Orange and Altice should continue to benefit from international diversification. While we remain cautious on the near term outlook at SFR, we believe the stock should be driven by Altice's exchange offer parity of 1.6.

RATING : NEUTRAL

Yesterday after trading, Ship Global 2 & Cy (a company jointly owned by funds managed by Advent International and Bain Capital) announced its intention to sell c.300m ordinary Worldpay shares, namely c.15% of the company's issued ordinary share capital. Any of these shares held by Ship Global 2 which are not sold in the placing will be subject to a 90-day lock-up. This is the 2nd placing this year (in March they sold 13.8% at 269p/share). We are waiting for the price but we now know that assuming all of the placing shares are sold, Ship Global 2 will continue to hold c.13.2% of the issued share capital of Worldpay. => Negative.

Fair Value 278p

ERYTechRATING : BUYFair Value EUR47 vs. EUR48H1 2016 results were in line with our estimates with the net loss at -EUR10.3m (vs BG: -EUR10.0m). But more
importantly, discussions with the CHMP might be longer than what management previously anticipated (Q1 2017).On the positive side, some issues have been "resolved"... But it might take more time for others. We have trimmed
our FV from EUR48 to EUR47 after having delayed our first sales estimates to the very beginning of 2018.

Sword GroupRATING : BUYFair Value EUR31 vs. EUR26 (+20%)We reiterate our Buy recommendation and raise our DCF-derived Fair Value to EUR31 from EUR26 as we reduce our
company beta to 2 from 2.2 and increase our adj. EPS ests. by 2-3% on updated fx assumptions. The analysts'
meeting held yesterday confirmed rosy prospects both for Software (driven by Apak) and IT Services (thanks to EU
contracts). We consider the 'Horizon 2020' plan is not aggressive on IfI sales growth, while the acquisition plan offers
flexibility for a larger purchase if the opportunity arises.

Fresenius SERATING : BUY-Top PicksFair Value EUR78 vs. EUR73Management's review of the growth prospect for Quirónsalud reinforce our sentiment on a perfect fit with Helios.Diluting KABI by bringing both stability and visibility to sales and earning ramps should be much appreciated in adifficult environment for the Pharmaceutical sector. Having integrated Quirónsalud in our model lift our 2017e EPSby 8.5%. We reiterate our BUY rating and raise our Fair Value from EUR73 to EUR78.